ApothéCure Recalls All Sterile Compounded Injectables
April 18, 2013
ApothéCure issued a nationwide recall of all lots of compounded sterile injectables with “Independently tested for sterility” on the vial. The recall is based on concerns with quality control and potential lack of sterility of the products. If the quality and sterility of a compounded product is compromised, patients could develop serious and potentially life-threatening infections. ApothéCure has had no reports of illness or injury attributed to the recalled products.
Discontinue use of all products and return them to ApothéCure. For more information, contact ApothéCure by phone (800-969-6601 or 972-960-6601) or by email (email@example.com).
FDA encourages consumers and healthcare professionals to report adverse reactions to FDA’s MedWatch Program at www.fda.gov/medwatch.
- MedWatch Alert:
- Firm Press Release:
April 18, 2013; University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT